gnbt fact sheet generex biotechnology corporation investor fact sheet glance symbol nasdaqsc gnbt price 3 4 05 0 61 52 week high low 0 58 1 86 av volume 3 mo 303 681 shares outstanding 34 76 million float 29 6 million held insiders 14 83 market capitalization 21 20 million cash 1 76 million long tem debt 935 000 revenue 710 000 10 31 04 12 months ended 10 31 04 insulin without pain ready market generex biotechnology nasdaqsc gnbt developed oral lyn oral insulin spray treatment diabetes thereby replacing insulin injections 10 years development oral lyn found effective injected insulin ready commercialization sales could start early first half 2005 south america canada europe next target market u europe follow diabetes growing epidemic rates hundreds millions suffer type 1 type 2 pre diabetes even modest penetration worldwide diabetes market would translate revenues billion dollar range generex delivery system rapidmist potential replace injected drugs including morphine fentanyl heparin flu vaccine buy generex biotechnology toronto based delaware corporation market ready solution central challenge diabetes treatment ending pain hassle insulin injections ever since scientists early 20 th century learned diabetes caused body inability produce normal supply insulin patients administer insulin injection alternatives developed recent years pumps needle less pens still invasive expensive pharmaceutical companies tried develop truly non invasive insulin product pain free easy use free serious side effects among today competing technologies oral lyn insulin spray treatment diabetes meets tests 10 years development oral lyn ready market set produce enormous revenue growth company generex little known outside small community investors focused drug delivery diabetes treatment next months however expected commercial entry oral lyn south america could raise generex profile sharply commensurate rise share price small companies drug medical device development course inherently high risk investments aggressive investors take early stake firms profit several times generex profile one potential winner readers advised investor fact sheet intended informational use anyone interested obtaining detailed information company contact generex biotechnology generex investor relations international iri investment profile developed part overall investor relations program iri iri retained generex provide investor relations advisory services iri receives compensation form cash investment fact sheet intended solely informational purposes construed offer sell solicitation offer buy company stock investment fact sheet based upon information available public well information sources deemed reliable guaranteed accurate purport complete investment fact sheet may contain forward looking statements within meaning section 27 securities act 1933 amended section 21 e securities exchange act 1934 amended forward looking statements subject variety risks uncertainties many beyond generex control could cause actual results differ materially contemplated forward looking statements existing prospective investors cautioned place undue reliance forward looking statements speak date hereof additional information regarding risks faced company visit company website www generex com message sent compliance federal spam bill electronic commerce ec directive regulations 2004 commercial email includes unsubscribe method remove processing mandated law footer also includes sender information bizcap info p box 155 sugarloaf ny 10981 excluded future mailings please reply email rem subject line